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Bruce A. C. Cree, MD, PhD, MAS, 4 on behalf of
the N-MOmentum scientific group and the N-MOmentum study investigators
Objective: Blood tests to monitor disease activity, attack severity, or treatment impact in neuromyelitis optica spec-
trum disorder (NMOSD) have not been developed. This study investigated the relationship between serum glial
fibrillary acidic protein (sGFAP) concentration and NMOSD activity and assessed the impact of inebilizumab treatment.
Methods: N-MOmentum was a prospective, multicenter, double-blind, placebo-controlled, randomized clinical trial in
adults with NMOSD. sGFAP levels were measured by single-molecule arrays (SIMOA) in 1,260 serial and attack-related
samples from 215 N-MOmentum participants (92% aquaporin 4-immunoglobulin G-seropositive) and in control sam-
ples (from healthy donors and patients with relapsing–remitting multiple sclerosis).
Results: At baseline, 62 participants (29%) exhibited high sGFAP concentrations (≥170 pg/ml; ≥2 standard deviations
above healthy donor mean concentration) and were more likely to experience an adjudicated attack than participants
with lower baseline concentrations (hazard ratio [95% confidence interval], 3.09 [1.6–6.1], p = 0.001). Median (inter-
quartile range [IQR]) concentrations increased within 1 week of an attack (baseline: 168.4, IQR = 128.9–449.7 pg/ml;
attack: 2,160.1, IQR = 302.7–9,455.0 pg/ml, p = 0.0015) and correlated with attack severity (median fold change from
baseline [FC], minor attacks: 1.06, IQR = 0.9–7.4; major attacks: 34.32, IQR = 8.7–107.5, p = 0.023). This attack-related
increase in sGFAP occurred primarily in placebo-treated participants (FC: 20.2, IQR = 4.4–98.3, p = 0.001) and was not
observed in inebilizumab-treated participants (FC: 1.1, IQR = 0.8–24.6, p > 0.05). Five participants (28%) with elevated
baseline sGFAP reported neurological symptoms leading to nonadjudicated attack assessments.
Interpretation: Serum GFAP may serve as a biomarker of NMOSD activity, attack risk, and treatment effects.
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Neuromyelitis optica spectrum disorder (NMOSD) isa rare, chronic, autoimmune, inflammatory disorder
of the central nervous system (CNS) characterized by
recurrent attacks of optic neuritis and longitudinally
extensive transverse myelitis, whereas brain and brainstem
inflammation are less frequently observed.1 Attacks can be
severe, with incomplete recovery leading to cumulative
disability.
Traditionally, immunosuppressants, such as corticoste-
roids, azathioprine, and mycophenolate mofetil,2 and
rituximab,3–5 are used to prevent attacks, although clinical evi-
dence for their effectiveness is limited and based on
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uncontrolled, retrospective, or small studies. Several new thera-
pies, including eculizumab, satralizumab, and inebilizumab,
were proven to be effective.6–9 Inebilizumab is a humanized,
affinity-optimized, afucosylated immunoglobulin G (IgG) 1κ
monoclonal antibody that binds to the B-cell-specific surface
antigen CD19 and depletes a wide range of B cells, as demon-
strated in preclinical animal models10 and in systemic
sclerosis,11 relapsing forms of multiple sclerosis (MS),12 and
NMOSD.8 The efficacy and safety of inebilizumab treatment
were evaluated in participants with NMOSD in the random-
ized, double-masked, placebo-controlled N-MOmentum
study.8 Compared with placebo, inebilizumab reduced the risk
of an attack by 73% (hazard ratio [HR] = 0.272, p < 0.0001)
and reduced the risk of disability worsening by 63% (odds
ratio = 0.370, p = 0.0049).
The presence of serum autoantibodies against
aquaporin 4 (AQP4) is a distinct feature of NMOSD and
distinguishes it from MS.13–15 AQP4 is a water channel
protein expressed predominantly on astrocytes and con-
centrated on the perivascular foot processes. Autoanti-
bodies to AQP4 are pathogenic in NMOSD,16,17
resulting in targeted astrocyte dysfunction and destruction.
Astrocyte injury results in the release of astrocyte contents
in cerebrospinal fluid (CSF) and serum,18–20 including
TABLE 1. Participant Demographics and Characteristics at Baseline (ITT sGFAP Analysis Set)
Demographic/characteristic
NMOSD
placebo (n = 51)
NMOSD
inebilizumab (n = 164)
RRMS
(n = 23) HD (n = 85)
Age, yr
Mean (SD) 43.4 (14.0) 43.0 (11.2) 45.3 (12.3) 43.4 (12.9)
Median (range) 43 (20–74) 43 (18–73) 44 (21–63) 43 (20–72)
Sex
F 45 (88) 149 (91) 14 (61) 88 (91)
Race/ethnicity
Asian 7 (14) 38 (23) 0 (0) 0 (0)
Black or African
American
5 (10) 14 (9) 3 (13) 5 (6)
Hispanic or Latino 14 (27) 27 (17) 1 (4) 13 (15)
White 23 (51) 82 (51) 17 (74) 63 (74)
Other 2 (4) 3 (8) 2 (4) 1 (1)
Disease duration, yr
Mean (SD) 2.8 (3.5) 2.4 (3.3) 8.9 (9.9) N/A
Median (IQR) 1.3 (0.2–16.9) 1.1 (0.1–22.2) 5.3 (0.2–36.0) N/A
Baseline EDSS score
Mean (SD) 4.2 (1.7) 3.8 (1.8) 3.9 (1.7) N/A
Median (IQR) 4.0 (1.0–8.0) 3.5 (0.0–8.0) 4.0 (0.0–6.5) N/A
Serostatus
AQP4-IgG seropositive 47 (92) 151 (92) N/A N/A
MOG-IgG seropositive 1 (2) 6 (4) N/A N/A
Double seronegative 3 (6) 7 (4) N/A N/A
sGFAP >170 pg/ml (%) 16 (31) 46 (28) 2 (9) 3 (4)
Data are n (%) unless stated otherwise. Race/ethnicity was self-reported by participants.
AQP4-IgG = aquaporin 4-immunoglobulin G; EDSS = Expanded Disability Status Scale; HD = healthy donors; IQR = interquartile range;
ITT = intention-to-treat; MOG-IgG = myelin oligodendrocyte glycoprotein-immunoglobulin G; N/A = not applicable; NMOSD = neuromyelitis
optica spectrum disorder; RRMS = relapsing–remitting multiple sclerosis; SD = standard deviation; sGFAP = serum glial fibrillary acidic protein.
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glial fibrillary acidic protein (GFAP), an intermediate fila-
ment protein predominantly expressed by astrocytes that
forms the astrocyte cytoskeleton.21 Therefore, serum
GFAP (sGFAP) could be a biomarker of disease activity in
NMOSD.
The aims of the current study were to investigate
the relationship between prospectively sampled sGFAP
concentration and disease activity in participants from the
N-MOmentum clinical trial and to assess the impact of
inebilizumab on sGFAP levels compared with placebo, a
predefined, exploratory study outcome.
Methods
Study Design and Participants
The sGFAP concentrations were assessed in participants
from the N-MOmentum study and in reference cohorts
of healthy donors and patients with relapsing–remitting
MS (RRMS).
Full details of theN-MOmentum study, including a trial
profile, were published.8 In brief, the N-MOmentum study
was an international, multicenter, randomized, double-blind,
placebo-controlled, phase II/III trial with an open-label exten-
sion phase (ClinicalTrials.gov, NCT02200770). Among the
clinically relevant inclusion criteria that helped define the study
population, criteria important for interpreting this manuscript
were the requirement for subjects with a recent attack to have
at least 4 weeks during which their attack symptoms were sta-
ble or improving prior to randomization, and that trial partici-
pants were not eligible for the study if they had received
intravenous immunoglobulin (IVIG) treatment within
1 month prior to randomization, or had received doses of
methotrexate or a range of other immunosuppressive
FIGURE 1: Baseline sGFAP concentration in the reference and NMOSD cohorts, and correlation of sGFAP with age. *p < 0.05;
**p < 0.01; **p < 0.001. (A) Graph shows baseline sGFAP concentrations by cohort and antibody serostatus. Dashed line
represents 2 SDs from the healthy donor mean (170 pg/ml). Box and whiskers represent sample quartiles. Statistical significance
of differences in sGFAP concentration between groups was assessed using the Mann–Whitney U test. (B and C) Graphs show the
correlation between age and baseline sGFAP concentration in both heathy donors and NMOSD participants. AQP4
+ = aquaporin 4-immunoglobulin G seropositive; DN = double negative serostatus; MOG+ = myelin oligodendrocyte
glycoprotein-immunoglobulin G seropositive; NMOSD = neuromyelitis optica spectrum disorder; RRMS = relapsing–remitting
multiple sclerosis; SD = standard deviation; sGFAP = serum glial fibrillary acidic protein.
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medications (cyclosporin, cyclophosphamide, eculizumab,
mitoxantrone, natalizumab, or tocilizumab) in the 3 months
prior to randomization. In addition, the study was designed to
investigate inebilizumab as monotherapy; no on-study immu-
notherapy was allowed beyond the tapering dose of steroids
given to all participants after infusion of inebilizumab or pla-
cebo. Baseline serum sampling for sGFAP occurred prior to
any of these study-related medications. The primary end point
was the time to an adjudicatedNMOSD attack during the ran-
domized controlled period (RCP). An attack was defined by
protocol-defined criteria1 upon neurological evaluation that
was adjudicated by an independent committee within 17 days.
Attack severity was graded according to the Opticospinal
Impairment Scale (OSIS),22,23 which characterizes attacks as
“minor” or “major” on the basis of changes in domain-specific
neurological scores relative to the previous assessment. Investi-
gators had the option of providing rescue therapy following an
attack, at their discretion and according to clinical need. Inves-
tigators were advised to give rescue therapy after the attack
assessment (including serum follow-up sampling), as not to
influence the data obtained.
Two reference cohorts of individuals without
NMOSD, one comprising age- and sex-matched healthy
donors (n = 85) and another comprising patients with
moderate-to-severe RRMS (baseline Expanded Disability Sta-
tus Scale [EDSS] score >3.5; n = 23) from the United States
and Europe described previously,12 were used as controls in
the assessment of the significance of sGFAP concentration in
NMOSD attack prediction and attack severity.
The study was conducted in accordance with the
International Conference on Harmonisation Guidelines
for Good Clinical Practice and the principles of the
Declaration of Helsinki. An institutional review board or
ethics committee at each study site approved the protocol.
Written informed consent was obtained from all
participants.
Sample Collection and Analysis
Blood was collected from N-MOmentum participants
during RCP study visits at baseline (day 1) and on days
15, 29, 57, 85, 113, 155, and 197, and during any assess-
ment visit for new or worsening NMOSD symptoms. For
the reference cohorts,12 participants were untreated and
blood was collected at the single baseline visit. Ten
healthy donors underwent repeated longitudinal sampling
for serial sGFAP measurements. As validated in serum
samples from patients with MS (aged 18–65 years with
confirmed relapsing forms of MS defined by the
McDonald 2010 criteria), with at least one relapse in the
last 3 years, EDSS score ≤6.5, normal baseline CD19 B-
cell count (>80 cells/μl) and no more than 20 gadolinium
(Gd)-enhancing lesions on magnetic resonance imaging
[MRI]) or traumatic brain injury,24,25 the sGFAP concen-
tration was determined using the single-molecule arrays
(SIMOA) GFAP assay by Quanterix (Lexington, MA,
USA). Elevated sGFAP concentrations were defined as
being ≥2 standard deviations (SDs) above the healthy
donor mean concentration (≥170 pg/ml) according to
established laboratory procedures.26
Statistical Analysis
NMOSD attacks were analyzed using Cox proportional
hazards regression. Statistical significance of regression
coefficients was assessed using Wald’s test. Differences
TABLE 2. Hazard Regressions of sGFAP Versus RCP Attack Frequency, Adjusted for Covariates
Variable name HR (95% CI) p value
Association between day 1 RCP
sGFAP and continuous variables
Association between day 1 RCP









3.20 (1.63, 6.26) <0.001 - - - -
Inebilizumab
treatment
0.28 (0.15, 0.53) <0.001 - - 0.51 (0.42, 0.61) 0.81
Attack <90 days
prior to RCP
0.45 (0.11, 2.07) 0.32 - - 0.52 (0.34, 0.70) 0.80
Age 0.98 (0.96, 1.01) 0.16 0.22 (0.09, 0.34) 0.001 - -
Baseline EDSS 1.08 (0.89, 1.31) 0.43 0.32 (0.20, 0.44) <0.001 - -
AUC = area under the curve; CI = confidence interval; EDSS = expanded disability status scale; HR = hazard ratio; RCP = randomized controlled
period; sGFAP = serum glial fibrillary acidic protein.
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in sGFAP concentration between groups were evaluated
using the Mann–Whitney U test for continuous mea-
sures, and either the Cochran–Armitage test or Fisher’s
exact test to test differences in proportions. Paired
changes in sGFAP concentration from baseline were
assessed using the Wilcoxon signed-rank test. The
Bonferroni correction was applied as a multiple testing
correction when appropriate and is described in the
corresponding figure legends. All statistical analysis was
performed in R version 3.6.2.
FIGURE 2: Attack-free survival in participants with NMOSD according to treatment and baseline sGFAP status. Graphs show
Kaplan–Meier plots of time until first NMOSD attack during the RCP in (A) placebo and (B) inebilizumab participants with
baseline sGFAP concentration ≥170 pg/ml versus those with baseline sGFAP concentration <170 pg/ml. Statistical significance of
difference in time until first adjudicated attack between groups was assessed using Wald’s test. (C and D) Graphs show Kaplan–
Meier plots of time until first attack between participants receiving inebilizumab or placebo with baseline sGFAP concentration
<170 pg/ml or ≥170 pg/ml. Statistical significance of difference in time until first adjudicated attack between groups was
assessed using Wald’s test. CI = confidence interval; EDSS = Expanded Disability Status Scale; HR = hazard ratio;
NMOSD = neuromyelitis optica spectrum disorder; RCP = randomized controlled period; sGFAP = serum glial fibrillary acidic
protein.
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In total, 215 participants (198 of whom were AQP4-IgG
seropositive) provided 1,260 serial and NMOSD attack-
related samples for sGFAP concentration analysis. Most
study participants were women (194/215 [90%]) and
approximately half were White (110/215 [51%]). Demo-
graphics were largely similar between the inebilizumab
(n = 164) and placebo (n = 51) groups (Table 1). In
addition, samples for sGFAP concentration analysis
were obtained from the reference cohorts of age- and
sex-matched healthy donors (n = 85) and untreated indi-
viduals with RRMS (n = 23; see Table 1).
sGFAP Concentration at Baseline in Participants
with NMOSD or RRMS and Healthy Donors
The sGFAP levels were defined as elevated when they
reached or surpassed 170 pg/ml, a threshold calculated as
2 SDs from the mean sGFAP concentration in healthy
donors. At study baseline, elevated sGFAP levels were
observed in significantly more participants with NMOSD
(62/215 [29%]) than individuals with RRMS (2/23 [9%])
or healthy donors (2/85 [2.4%]); p < 0.05 and p < 0.001,
respectively (Fig 1A). Median (interquartile range [IQR])
sGFAP concentration was 128.3 pg/ml (IQR = 92.0–181.2
pg/ml) for participants with NMOSD, compared with 71.3
pg/ml (IQR = 55.6–102.2 pg/ml) for age- and sex-matched
healthy donors and 97.5 pg/ml (76.5–131.4 pg/ml) for
individuals with RRMS. Two AQP4-IgG-seronegative par-
ticipants (one of whom was myelin oligodendrocyte glyco-
protein (MOG)-IgG seropositive) had elevated sGFAP levels
at baseline (see Fig 1A). For both patients with NMOSD
and healthy donors, we observed a modest but clear correla-
tion of sGFAP levels with age (Fig 1B, C) and EDSS score
(Table 2), whereas sex or race/ethnicity had no effect.
Participants with Elevated sGFAP
Concentrations Are at Increased Risk of Attacks
Participants with NMOSD and with an elevated baseline
sGFAP concentration were at increased risk of experienc-
ing an adjudicated NMOSD attack. Analysis of all study
participants showed that 19 of 62 patients (31%) with an
elevated sGFAP concentration at baseline experienced an
adjudicated NMOSD attack during the 28-week RCP ver-
sus 19 of 153 patients (12%) without elevated sGFAP,
equating to 3 times the risk of an attack during the RCP
(HR = 3.09, 95% confidence interval [CI] = 1.57–6.10,
p = 0.001). A similar pattern was observed for both the pla-
cebo and the inebilizumab groups (for placebo: HR = 2.35,
95% CI = 0.94–5.87, p = 0.06; for inebilizumab:
HR = 4.15, 95% CI = 1.67–10.32, p = 0.002; Fig 2A, B).
In participants with elevated baseline sGFAP con-
centrations, inebilizumab reduced the risk of an adjudi-
cated attack by 61% compared with placebo (HR = 0.39,
95% CI = 0.15–0.96, p = 0.041; Fig 2C). In participants
without elevated baseline sGFAP levels, the risk of an
adjudicated attack was reduced by 79% with inebilizumab
compared with placebo (HR = 0.21, 95% CI = 0.08–
0.51, p < 0.001; Fig 2D). The association between sGFAP
and upcoming attacks was significant when controlling for
recent attacks, age, and baseline EDSS (see Table 2).
sGFAP Concentration Increases during NMOSD
Attacks and Correlates with Attack Severity
Significant increases in sGFAP concentrations from baseline
were observed for participants within 1 week (either before or
after) of adjudicated NMOSD attacks (Fig 3A, median, pre-
attack (baseline) samples: 168.4, IQR = 128.9–449.7 pg/ml;
attack samples: 2,160.1, IQR = 302.7–9,455.0 pg/ml,
p = 0.0015). Indeed, sGFAP appears to be linearly correlated
with upcoming attack risk. Notably, serum sampling was
performed prior to initiation of attack therapy, and
increases in sGFAP levels were not observed in the major-
ity of samples drawn greater than 1 week prior to attack.
An elevated sGFAP concentration (≥170 pg/ml) was
observed in 29 of 37 attack samples (78%) compared with
19 of 38 pre-attack samples (50%). Eight of 37 samples
(21.6%) obtained from participants during adjudicated attacks
did not have elevated sGFAP levels; 7 were from inebilizumab-
treated participants and 1 was from a placebo-treated partici-
pant receiving placebo (7/20 [35%] vs 1/17 [6%]; Fisher’s
exact test, p = 0.048).
FIGURE 3: The sGFAP concentration at baseline at visits leading to an adjudicated NMOSD attack, and during attack. (A) Graph
shows a boxplot of sGFAP measurements leading up to attack in 38 participants who experienced an adjudicated attack and
provided sGFAP measurements. Baseline samples >5 weeks from attack were available in 30 of 38 participants. Eight
participants experienced attacks within 5 weeks of the baseline sample collection. (B) Graph shows a profile plot of sGFAP
measurements in the days leading up to the attack. Graphs show sGFAP concentration of samples drawn most proximal to
attack and within 1 week of adjudicated NMOSD attack by attack severity (C) and organ domain involvement (D), measured by
the OSIS. Of the attacks across multiple domains, 4 were minor myelitis attacks, and one sample from myelitis major group
displayed sGFAP within the healthy donor range. Box and whiskers represent sample quartiles. Statistical significance between
groups was assessed using Mann–Whitney U test. Dashed lines represent 2 SDs from the healthy donor mean (170 pg/ml).
NMOSD = neuromyelitis optica spectrum disorder; ON = optic neuritis; OSIS = Opticospinal Impairment Scale;
RCP = randomized controlled period; SD = standard deviation; sGFAP = serum glial fibrillary acidic protein.
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No significant trend was observed between sGFAP
concentration and time since attack within the 1-week
window. Seven samples (5 placebo-treated and
2 inebilizumab-treated) of the 8 drawn up to 1 week prior
to the attack displayed sGFAP above healthy donor range
and were increased relative to each participant’s value at
baseline (ie, day 1 of the RCP). Similarly, 12 of 13 samples
(7 placebo- and 6 inebilizumab-treated participants)
drawn in the days after the attack displayed sGFAP above
healthy donor range (see Fig 3A). One inebilizumab-
treated subject displayed sGFAP within healthy donor
range 2 days after attack onset. Seven out of the 9 samples
with sGFAP concentrations below healthy donor range
were drawn during attack assessments performed on the
same day as attack onset, 6 of which were drawn from
inebilizumab-treated participants (see Fig 3B).
Following the attack assessments, serum samples
were drawn again per study protocol at day 15 of the
open-label period (OLP) at the earliest – more than
5 weeks after attack onset for the majority of participants.
By this time point, sGFAP largely returned to concentra-
tions comparable to those observed for the given partici-
pants at baseline, with 12 of 35 (34%) samples drawn
following attack above 170 pg/ml. Eight of these samples
were drawn from placebo-treated participants, and 4 from
inebilizumab-treated subjects. Moreover, 5 samples were
drawn earlier than 5 weeks after the attack. Of these
5 samples, 2 (40%) displayed sGFAP concentrations
higher than 170 pg/ml, thus similar to the distribution of
sGFAP levels in NMOSD samples drawn at baseline (see
Fig 3B).
Elevated sGFAP concentration was associated with
adjudicated-attack severity as determined by the OSIS.
The sGFAP concentration during an attack was signifi-
cantly higher in participants who had major attacks than
in those who had minor attacks (median fold change
FIGURE 4: The sGFAP concentration during adjudicated NMOSD attacks. (A and B) Graphs show sGFAP concentration of most
proximal samples drawn within 1 week of attack according to treatment in participants with attacks. Statistical significance of
increases from baseline was assessed using the Wilcoxon signed-rank test. Dashed line represents sGFAP concentration 2 SDs
from the healthy donor mean (170 pg/ml). (C) Graph displays time course of FC in sGFAP from baseline in the weeks leading up
to and proceeding adjudicated attacks. Points represent medians, error bars represent IQR. (D) The sGFAP concentration during
adjudicated NMOSD attacks according to treatment group and antibody serostatus. Box and whiskers represent sample
quartiles. DN = double negative serostatus; FC = fold change; IQR = interquartile range; MOG+ = myelin oligodendrocyte
glycoprotein-immunoglobulin G seropositive; RCP = randomized controlled period; SD = standard deviation; sGFAP = serum
glial fibrillary acidic protein.
FIGURE 5: Change in sGFAP concentration from baseline in participants who did not experience an adjudicated NMOSD attack.
(A) Graph shows change in sGFAP concentration over time in participants without attacks. Error bars represent interquartile
range. Statistical significance of percentage change from baseline, comparing inebilizumab to placebo, was assessed using the
Mann–Whitney U test; *p < 0.05; **p < 0.01; ***p < 0.001; week 16 changes from baseline remained significant (adjusted
p value < 0.05) between dose groups after the Bonferroni correction was applied to p values. Nineteen of 117 (16%)
inebilizumab samples and 9/26 (35%) placebo samples were outside healthy donor range (Fisher’s exact test, p = 0.052). (B)
Graph shows proportion of participants with elevated sGFAP concentrations (≥170 pg/ml) at week 28 of the RCP in participants
receiving placebo or inebilizumab. FC = fold change; NMOSD = neuromyelitis optica spectrum disorder; RCP = randomized
controlled period; sGFAP = serum glial fibrillary acidic protein.
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[IQR], major attacks: 34.32, IQR = 8.72–107.53; minor
attacks: 1.06, IQR = 0.85–7.43, p = 0.023; see Fig 3C).
The sGFAP levels were increased during major attacks of
both myelitis and optic neuritis (see Fig 3D).
At the time of adjudicated NMOSD attacks, sGFAP
concentration increased significantly from baseline in
placebo-treated participants (median fold change, 20.2,
IQR = 4.4–98.3, p = 0.001; Fig 4A). This was not the
case in the majority of inebilizumab-treated participants
(median fold change, 1.1, IQR = 0.8–24.6, p = 0.31;
Fig 4B), although a subset of 7 of 18 (39%)
inebilizumab-treated participants with paired baseline and
attack samples displayed significant increases from baseline
(median fold change, 75.7, IQR = 24.5–171.4; time
course of fold changes from baseline displayed in Fig 4C).
Absolute sGFAP levels were also significantly lower in
inebilizumab-treated participants than in the placebo
group (median: inebilizumab [n = 20], 653.0,
IQR = 139.0–7,227.8 pg/ml; placebo [n = 17], 3,056.1,
IQR = 1,091.5–15,858.5 pg/ml, p = 0.048; see Fig 4A,
B). None of the 3 inebilizumab-treated AQP4-IgG-
seronegative patients who experienced attacks exhibited
increases in sGFAP (Fig 4D).
sGFAP Concentrations in Participants Who Did
Not Experience an Adjudicated NMOSD Attack
For participants who did not experience an adjudicated
NMOSD attack during the RCP, sGFAP concentration
FIGURE 6: The sGFAP increases in participants without adjudicated attacks are correlated with disease activity. (A) Profile plot of
longitudinal fold change from baseline in sGFAP concentration in participants with NMOSD who experienced adjudicated
attacks (gold), those who did not experience adjudicated attacks but displayed an increase greater than twofold from baseline
(blue), and in those who neither experienced attacks nor displayed increases greater than twofold from baseline (gray) in sGFAP
during the RCP. (B) Boxplots displaying sGFAP concentrations observed in 10 healthy controls across 3 blood draws. Proportion
of (C) new spinal cord T2 or (D) Gd-enhancing T1 lesions observed in participants who did not experience committee-adjudicated
attacks and had MRI scans, but either did or did not display a greater than twofold increase in sGFAP during the RCP. (E) Bar
chart shows proportion of participants with an increase greater than twofold in sGFAP from baseline. The total number of
participants at each time point represent those remaining in the RCP with available sGFAP data. Statistical significance in the
between-group difference was assessed using the Cochran–Armitage test, *p < 0.05; **p < 0.01; ***p < 0.001, week 16 changes
from baseline remained significant (adjusted p value < 0.05) after the Bonferroni correction was applied to p values.
AC = adjudication committee; CI = confidence interval; FC = fold change; Gd = gadolinium; MRI = magnetic resonance imaging;
NMOSD = neuromyelitis optica spectrum disorder; OR = odds ratio; RCP = randomized controlled period; sGFAP = serum glial
fibrillary acidic protein.
TABLE 3. Overview of AEs and SAEs in Attack-Free Participants with sGFAP Increases
Field
Any AE in RCP Any SAE in RCP
Participants with AE and no sGFAP
increase, No. (%)
116/158 (73%) 7/158 (4%)
Participants with AE and sGFAP
increase, No. (%)
15/18 (83%) 1/18 (6%)
No sGFAP increase, median AE count
(Q1, Q3)
2 (0, 4) 0 (0, 0)
sGFAP increase, median AE count (Q1,
Q3)
3 (1, 4) 0 (0, 0)
No sGFAP increase, mean AE count
(SEM)
2.99 (2.66–3.33) 0.06 (0.03–0.08)
sGFAP increase, mean AE count (SEM) 4.67 (3.24–6.09) 0.17 (0.00–0.33)
RR (95% CI) 1.56 (2.81–0.87) 2.93 (26.9–0.32)
NB regression p value 0.139 0.343
Negative binomial regression of the number of AEs in participants without attacks and with or without sGFAP increases.
AE = adverse event; CI = confidence interval; NB = negative binomial; OR = odds ratio; Q = quartile; RCP = randomized controlled period; RR = risk
ratio; SAE = severe AE; SEM = standard error of the mean; sGFAP = serum glial fibrillary acidic protein.
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decreased with inebilizumab treatment after week 4. The
percentage reduction from baseline was statistically signifi-
cant at week 16 (median reduction of 12.9%, IQR =
−25.6 to −1.6) and on to the end of the RCP (p < 0.05;
Fig 5A). Conversely, there was no significant change in
sGFAP levels in participants receiving placebo without
attacks (p > 0.05; see Fig 4D). By the end of the RCP,
9 of 26 participants (35%) within the placebo group had
elevated sGFAP concentrations, compared with 19 of
117 participants (16%) within the inebilizumab group
(Fig 5B).
Among the 177 participants without an attack,
18 (10.2%) displayed an increase greater than twofold in
sGFAP concentration in at least one sample draw. These
increases from baseline were comparable to the range
observed in participants with attacks (Fig 6A) and well
outside the variation observed in longitudinal draws from
healthy donors, although the time frames of sample acqui-
sition from healthy donors and N-MOmentum partici-
pants were different (Fig 6B). Five of these 18 participants
(28%) with an elevation in sGFAP reported neurological
symptoms that were rated as attacks by the treating
investigators but not confirmed by the adjudication com-
mittee. Of note, for the total cohort of these 18 partici-
pants, an increased rate of adverse events in temporal
vicinity to sampling was observed (Tables 3 and 4). More-
over, of the subgroup of 16 attack-free participants who
had increases greater than twofold in sGFAP concentra-
tion and had spinal cord MRI scans, 9 (56%) presented
with new or enlarging T2 lesions versus 9 (6%) of the
143 participants who neither experienced attacks nor dis-
played longitudinal sGFAP level changes (Fig 6C). A simi-
lar pattern was seen for Gd-enhancing T1 spine lesions
(Fig 6D). The proportion of participants with twofold
increases in sGFAP levels was reduced by treatment with
inebilizumab from week 12 onward (Fig 6E).
Discussion
In NMOSD, astroglial injury results in release of GFAP
into the parenchymal interstitial fluid, subsequently
detectable in the CSF and serum.27,28 Given that sGFAP
is derived predominantly from the CNS,29 detection of
GFAP may be particularly important in NMOSD because
TABLE 4. Overview of AEs and SAEs in Relation to Time of sGFAP Sample Collection in Attack-Free Participants
with sGFAP Increases
Field
Samples with AE and no
sGFAP increase, No. (%)
Samples with AE and





7 days of sample
220/1,015 (21.7%) 9/23 (39%) 2.32 (0.87–5.85) 0.07
Any AE within
14 days of sample
257/1,015 (25.3%) 12/23 (52%) 3.21 (1.28–8.15) 0.007
Any AE within
30 days of sample
328/1,015 (32.3%) 12/23 (52%) 2.29 (0.91–5.78) 0.07
Any AE within
45 days of sample
386/1,015 (38.0%) 13/23 (57%) 2.12 (0.85–5.45) 0.08
SAEs
Any SAE within
7 days of sample
5/1,015 (0.5%) 2/23 (9%) 19.01 (1.72–124) 0.009
Any SAE within
14 days of sample
9/1,015 (0.9%) 2/23 (9%) 10.57 (1.05–55.8) 0.02
Any SAE within
30 days of sample
13/1,015 (1.3%) 2/23 (9%) 7.30 (0.75–35.6) 0.04
Any SAE within
45 days of sample
16/1,015 (1.6%) 2/23 (9%) 5.92 (0.62–27.9) 0.06
AE = adverse event; CI = confidence interval; OR = odds ratio; Q = quartile; SAE = severe adverse event; sGFAP = serum glial fibrillary acidic protein.
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it is directly linked to the astrocyte damage underlying
lesion formation.16,17
The concentration of GFAP in the CSF is raised in
NMOSD and MS compared with healthy conditions.30 In
NMOSD, CSF GFAP concentration correlates with EDSS
score and with the length of spinal cord involvement. CSF
GFAP concentration increases during attacks and falls follow-
ing successful corticosteroid treatment.31–33 However, mea-
surement of CSF GFAP concentrations is unsuitable for
frequent sampling. We chose to measure sGFAP concentra-
tions using the SIMOA assay, which allows reliable detection
of picomolar concentrations of CNS-derived proteins in
blood.34,35 CSF and serum GFAP concentrations correlate
strongly in patients with MS and NMOSD.36,37
Our analyses confirmed that sGFAP concentration is
often raised in untreated participants with NMOSD com-
pared with both healthy donors and patients with RRMS.
Of note, regarding the definition of physiological ranges,
we observed a clear age-dependent increase of sGFAP in
all cohorts, including age- and sex-matched healthy
donors, and we were able to confirm the previously
reported correlation of sGFAP with EDSS.37 For
NMOSD, neuropathology shows that astrocyte damage is
more severe than in MS; consequently, the concentration
of GFAP can be far greater than that detected in patients
with MS, further supporting the use of sGFAP as a poten-
tial biomarker in NMOSD.37
The risk of an adjudicated attack in participants who
had elevated levels of baseline sGFAP was 3 times higher
than in those with lower sGFAP concentration. This find-
ing suggests that subclinical astrocyte injury or enhanced
blood–brain barrier permeability may occur as a long-
range prelude to an acute attack. Clinical attacks might
occur when a certain threshold of astrocytic injury is sur-
passed or if compensatory mechanisms that would other-
wise suppress inflammation or restore neurologic function
are overcome. Indeed, sGFAP concentration was raised in
some participants without an adjudicated attack. Subclini-
cal tissue injury in patients with NMOSD is not well-rec-
ognized, although the occurrence of clinically silent brain
lesions,38 cervical spinal cord atrophy,39 retinal
thinning,40-42 and changes in visual evoked potentials43,44
were reported. Indeed, we observed that elevated sGFAP
levels detected in participants without adjudicated attacks
were associated with new or enhanced MRI activity as well
as with adverse events, including patient-reported com-
plaints. Alternatively, the increased frequency of enhanced
MRI activity may also indicate that enhanced blood–brain
barrier permeability is facilitating the transit of GFAP to
the peripheral circulation.
In clinical practice, the current goal of disease-
modifying therapy is to induce a state of clinical
remission. Our data suggest that normalizing sGFAP levels
might also guide treatment, in the context of clinical
parameters.
Our analysis showed that CD19-mediated B-cell deple-
tion by inebilizumab decreased the risk of attack versus pla-
cebo regardless of baseline sGFAP concentration, although
risk reduction was less prominent in participants with ele-
vated baseline sGFAP than in those with lower baseline
levels. This suggests that patients with higher baseline sGFAP
concentrations may be undergoing subclinical astrocytic
damage prior to onset of clinical symptoms.
We also observed that sGFAP concentration
increased during adjudicated attacks compared with base-
line. The increase in attack risk in participants was based
on a cutoff relative to healthy donors. However, because a
linear relationship appears to exist between sGFAP con-
centration and attack risk, in the future, one could poten-
tially define different strata of attack risk. Furthermore,
greater attack severity was associated with higher sGFAP
concentrations, even if the attack affected only the optic
nerve(s). Our findings are also consistent with the results
of a recent study in which sGFAP concentration was
shown to increase during an NMOSD attack.37
In participants receiving inebilizumab who experi-
enced an attack, sGFAP concentration was nevertheless
lower than in participants receiving placebo, and in the
subset of inebilizumab-treated participants who experi-
enced an attack, sGFAP did not significantly increase
compared to the baseline samples. Inebilizumab decreased
sGFAP concentration in participants without an adjudi-
cated attack, and fewer inebilizumab-treated participants
had raised sGFAP levels compared with placebo-treated
participants, indicating a potential protective effect of B-
cell depletion regardless of attack status. B-cell depletion
by inebilizumab could interfere with both the activity of B
cells and the detrimental effects of circulating AQP4-IgG
on astrocytic endfeet that are a component of the func-
tional blood–brain barrier. In turn, astrocyte injury
(reduced soluble GFAP production) may be lessened, and
blood–brain barrier stability (reduced access of soluble
GFAP to serum) enhanced. In combination, the result is
decreased concentration of GFAP in the circulation. As
increased levels of sGFAP were correlated with attack
severity, participants who experienced less severe attacks
would have reduced levels of sGFAP, which in tandem
with the hypothesized beneficial effects of inebilizumab on
astrocyte damage and blood–brain barrier permeability,
may lead to a stabilization of sGFAP concentrations.
Finally, it remains to be clarified whether access of soluble
GFAP to the circulation during quiescence and NMOSD
activity is mediated exclusively through a leaky blood–
brain barrier or is facilitated by CNS glymphatics.45,46
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Several questions remain unanswered by the present
study. Although an expert adjudication committee con-
firmed all attacks, a new enhancing MRI lesion was not
required for determination of all attacks. Further study is
needed to determine whether radiographically silent, clini-
cally adjudicated attacks are associated with sGFAP eleva-
tion. Pseudo-attacks can occur in NMOSD and may be
difficult to diagnose clinically. Presumably, sGFAP con-
centration would not be elevated in pseudo-attacks and
sGFAP measurement could be a less costly and more
accessible option for accurate attack diagnosis. Moreover,
regarding our data on timing of sGFAP changes during
attack onset, it is possible that unspecific but attack-driven
clinical symptoms may have started before formal onset of
an attack, depending on an individual patient’s awareness
and willingness to report such changes.
There are limitations in interpreting our results.
NMOSD is a rare disease and recruiting large numbers of
participants was challenging. Although the N-
MOmentum study was adequately powered to detect
treatment effects for major end points, the study was not
designed to show statistically significant effects for all sub-
groups. For example, sample size limitations are apparent
for the AQP4-IgG-seronegative participants (N = 17) and
the even smaller MOG-IgG-seropositive subset (N = 7).
Although we presented data on the intention-to-treat pop-
ulation, the sGFAP results are driven almost entirely by
observations from the AQP4-IgG-seropositive subgroup.
Furthermore, because of the 3:1 randomization in the
study, the size of the placebo group was small and
decreased further as the study progressed because of the
crossover to open-label treatment following adjudicated
attacks and the subsequent exit from the RCP. Therefore,
the limited placebo group data at later time points of the
RCP reduced the power to detect treatment differences.
N-MOmentum was also a single trial, and replication in
other prospectively gathered data sets with inebilizumab
and other treatments is needed. For the time being,
sGFAP cannot be assessed by point-of-care testing as one
might wish for acute attack assessment. Until technologi-
cal advances enable rapid testing, sGFAP can only be
assessed by specialized laboratories. Nonetheless, there is
potential for sGFAP’s application to stratify risk and assess
therapeutic benefit, at least in patients undergoing B-cell
depletion. Despite these important limitations, the trends
reported here were notably consistent, and the predefined
analyses strengthen the validity of the results.
In conclusion, data from the N-MOmentum study
show that sGFAP may be a clinically informative bio-
marker for both attack risk and severity. The sGFAP ele-
vation in some participants without clinical attacks but
with new MRI lesions reveals that subclinical disease
activity and/or blood–brain barrier breakdown may be
present in NMOSD. These results underscore the poten-
tial of soluble CNS-derived biomarkers like GFAP for the
assessment of ongoing neural injury and thus, the identifi-
cation of patients with NMOSD at risk for relapse.
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